Neon Therapeutics, Inc. Common Stock
NTGN
NTGN was delisted on the 5th of May, 2020.
51 hedge funds and large institutions have $90.2M invested in Neon Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 17
2% less funds holding
Funds holding: 52 → 51 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
29% less capital invested
Capital invested by funds: $127M → $90.2M (-$37.1M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$446K |
| 2 |
State Street
Boston,
Massachusetts
|
+$431K |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$226K |
| 4 |
Bank of New York Mellon
New York
|
+$211K |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$176K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$1.68M |
| 2 |
PIM
Partner Investment Management
San Francisco,
California
|
-$1.43M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$1.37M |
| 4 |
JP Morgan Chase
New York
|
-$582K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$447K |
NTGN Hedge Fund Activity: Q2 2019 in Review
51 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Neon Therapeutics, Inc. Common Stock (NTGN) for Q2 2019, worth a combined $90.2M — down 29% from $127M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of NTGN and 4 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 17 added.
The largest buyer was BlackRock, adding an estimated $446K. The largest seller was PFM Health Sciences, cutting an estimated $1.68M.
- 51 institutional investors held Neon Therapeutics, Inc. Common Stock (NTGN) as of Q2 2019, down from 52 in Q1 2019.
- Funds reported $90.2M of Neon Therapeutics, Inc. Common Stock stock for Q2 2019, down 29% quarter-over-quarter.
- 4 funds opened new Neon Therapeutics, Inc. Common Stock positions in Q2 2019 and 5 closed out, a net change of -1 holder.
- The largest Neon Therapeutics, Inc. Common Stock buyer in Q2 2019 was BlackRock, an estimated $446K added.
- The largest Neon Therapeutics, Inc. Common Stock seller in Q2 2019 was PFM Health Sciences, an estimated $1.68M sold.
Based on aggregated 13F filings for Q2 2019.